AIM ImmunoTech

AIM ImmunoTech Total Assets

The Total Assets of AIM ImmunoTech (AIM) as of Oct 17, 2026 is 5.78 M USD. In the previous year, Total Assets was 8.61 M USD — a change of -32.83% (lower).

Total Assets

5.78 MUSD

YoY

-32.83%

Last updated:

Total Assets of AIM ImmunoTech is 2025 5.78 M USD. Total Assets of AIM ImmunoTech was 2024 8.61 M USD. It decreases by -32.83% lower compared to the previous year.

The AIM ImmunoTech Total Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Total Assets
Date
Total Assets
Jan 1, 2018
13.85 M USD
Jan 1, 2019
20.22 M USD
Jan 1, 2020
111.02 M USD
Jan 1, 2021
57.70 M USD
Jan 1, 2022
40.49 M USD
Jan 1, 2023
19.38 M USD
Jan 1, 2024
8.61 M USD
Jan 1, 2025
5.78 M USD
The AIM ImmunoTech Total Assets history
YEARTotal AssetsYoY
5.78 MUSD-32.83%
8.61 MUSD-55.59%
19.38 MUSD-52.13%
40.49 MUSD-29.83%
57.70 MUSD-48.03%
111.02 MUSD+449.09%
20.22 MUSD+46.04%
13.85 MUSD-2.55%
14.21 MUSD-24.72%
18.87 MUSD-17.24%
22.80 MUSD-22.54%
29.44 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AIM ImmunoTech Stock analysis

What does AIM ImmunoTech do? AIM ImmunoTech Inc is a biotechnology company based in Ocala, Florida, operating within the health care sector. The company focuses on the clinical development of drug therapies utilizing natural immune system enhancing technologies for treating viral and immune-based disorders. It employs 31 full-time staff members. AIM ImmunoTech's primary products include Alferon N Injection, approved for intralesional treatment of refractory or recurring external genital warts in patients over 18, and Ampligen, which is under clinical development for Chronic Fatigue Syndrome (CFS). The company also develops Alferon LDO, a low-dose oral liquid formulation of natural alpha interferon. AIM ImmunoTech went public on July 12, 1996, with its ticker symbol AIM and ISIN US00901B3033. Its website is hemispherx.net. The company's operations are centered around research and development activities related to Ampligen and other drugs in development, alongside sales and marketing of Alferon. The firm's activities are primarily directed toward addressing chronic viral and immune-related conditions through innovative therapeutic approaches. AIM ImmunoTech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AIM ImmunoTech stock

Total Assets of AIM ImmunoTech is 5.78 M USD in 2025.

Total Assets of AIM ImmunoTech changed from 8.61 M USD to 5.78 M USD, representing a -32.83% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Assets AIM ImmunoTech since 2006 – with annual values, charts, and detailed analysis.

Total assets represent everything a company owns, including cash, inventory, property, and intangible assets. It is a key measure of a company's size and resource base.

Total Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Assets's AIM ImmunoTech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — AIM ImmunoTech

All Key Metrics — AIM ImmunoTech